Bortezomib plus dexamethasone results in a late organ response in primary heavy-chain amyloidosis without a hematologic response.
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Yasmin
Y
Hassoun
Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; Department of Oncologic Sciences, University of South Florida College of Medicine, Tampa, FL, USA.
Mohamed A
MA
Kharfan-Dabaja
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; Department of Oncologic Sciences, University of South Florida College of Medicine, Tampa, FL, USA. Electronic address: Rachid.Baz@MOFFITT.org.
Rachid
R
Baz
D000686:Amyloidosis / Q000150:complications / Q000188:drug therapy*; D000740:Anemia / Q000150:complications; D001706:Biopsy; D000069286:Bortezomib / Q000008:administration & dosage*; D003907:Dexamethasone / Q000008:administration & dosage*; D018450:Disease Progression; D005923:Glomerulosclerosis, Focal Segmental / Q000150:complications; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000737:chemistry; D000075363:Immunoglobulin Light-chain Amyloidosis; D008297:Male; D008856:Microscopy, Fluorescence; D008875:Middle Aged; D011507:Proteinuria / Q000150:complications; D051437:Renal Insufficiency / Q000150:complications; D016896:Treatment Outcome
D005938:Glucocorticoids; D007143:Immunoglobulin Heavy Chains; D000069286:Bortezomib; D003907:Dexamethasone